Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271412 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
A Phase 1 study, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT02271412 is a Phase 1 study that has completed, run by Luye Pharma Group. The registered enrollment target is 58 participants.
The verdict
NCT02271412, a Phase 1 study, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
Objectives * To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. * To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
Interventions
- DRUG Placebo
- DRUG LY03005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02271412
The ClinicalTrials.gov registry entry for NCT02271412 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02271412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02271412 about?
NCT02271412 is a clinical study titled "Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005". Objectives * To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. * To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
What is the current status of trial NCT02271412?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2014-10. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02271412?
The interventions under investigation include: Placebo (DRUG), LY03005 (DRUG).
Who is sponsoring clinical trial NCT02271412?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.